A membranous CD138 immunostaining was earlier described in 26% of 196 localized cancers [15], 83% of 5 metastatic cancers [15], 35% of 42 hormone-refractory cancers [15], 19% of 103 [25], and 36% of 60 cancers [20]. This evidence concerns the gene SDC1 and metastatic malignant neoplasm.